BRETEC — Bioretec Oy Share News
0.000.00%
Last trade - 00:00- €28.71m
- €16.69m
- €3.52m
Brief: Bioretec Is Planning Rights Issue Of At Least EUR 5 Mln, Up To EUR 15 Mln
Finland's Bioretec posts 22.5% drop in 2025 net sales, withdraws previous financial targets
Brief: Bioretec Proposes No Dividend To Be Distributed For 2025
Brief: Bioretec Mulss Rights Issue
Brief: Bioretec Names Tuukka Paavola As CFO
Brief: Bioretec Targets Net Sales Exceeding EUR 10 Mln By 2028
Brief: Bioretec Has Been Granted FDA Breakthrough Device Designation Status For Its Remeos Drillpin
Brief: Change Negotiations Completed At Bioretec
Brief: Bioretec: Change Negotiations Completed
Brief: Bioretec 9M EBITDA EUR -6.325 Million
Brief: Bioretec Starts Change Negotiations
Brief: Bioretec Adjusts And Restates Previously Reported Net Sales For H1/2025 And Does Not Expect Accelerated Sales In 2025
Brief: Bioretec Withdraws Financial Targets
Brief: Bioretec's RemeOs™ Screw Receives Medicare Payment Approval in US
Brief: Bioretec's Remeos Screw Lag Solid Gets CMS TPT In The US
Brief: Anne-Mari Matikainen Appointed As Interim CFO Of Bioretec
Brief: Bioretec Extends Timeline For DrillPin Commercialization In 2025
Brief: Bioretec Appoints Dr. Christopher W. Digiovanni To Scientific Advisory Board
Brief: Bioretec Appoints Sarah Van Hellenberg Hubar-Fisher As CEO